Rgenta Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, developing oral, small-molecule medicines that target RNA to treat diseases long considered undruggable. Its platform mines human genomic data to identify targetable RNA-processing events and designs small-molecule glues that modulate splicing, driving lead oncology candidate RGT-61159 — an oral MYB inhibitor with FDA orphan drug designation for adenoid cystic carcinoma that has aligned with FDA on a Phase 3 trial design — plus a CNS program for repeat-expansion disorders such as Huntington's disease. The company has formed strategic alliances with GSK and Lundbeck.
1
Round
1
Industry
5
Tags
Nov 3, 2026
Latest raise
Funding activity · 1 round
Nov 3, 2026
$41.9M
Series B
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
